bachelor's at Medicina from Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (1981), bachelor's at Medicina from Pontifícia Universidade Católica de Campinas (1978) and doctorate at Medicina from Universidade de São Paulo (1991). Has experience in Medicine, focusing on Rheumatology, acting on the following subjects: systemic lupus erythematosus, lúpus eritematoso sistêmico, autoantibodies, auto-anticorpos and atherosclerosis. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
One of the main causes of morbidity and mortality in patients with autoimmune rheumatic diseases (ARD) is acute and chronic infections. Several publications from our group reinforce the greater susceptibility, worse course and prognosis of various infectious diseases caused by viruses, bacteria and opportunistic agents (fungi and tuberculosis) in patients with ARD. Vaccination is the most…
The rapid expansion of the COVID-19 pandemic in the world caused the need to adopt new strategies for the organization of health systems and services. In a scenario where the demand quickly exceeded the usual capacity of health services, especially in relation to beds in intensive care units (ICU), there was an urgent need to increase this structure and offer it to the network. In this co…
No drug treatment is completely free of risk and lack of response, adverse events and poor adherence may affect its effectiveness. There is also a large inter-individual variability in response to treatments with regard to efficacy and toxicity, and for many drugs, there is also a period of weeks to months to establish its efficacy. In this regard, this project aims to evaluate the import…
No drug treatment is completely free of risk and lack of response, adverse events and poor adherence may affect its effectiveness. There is also a large inter-individual variability in response to treatments with regard to efficacy and toxicity, and for many drugs, there is also a period of weeks to months to establish its efficacy. Within this context, this project aims to evaluate the i…
(Only some records are available in English at this moment)
Coronavirus 2019 disease (COVID-19) has proven to be the biggest health challenge since 2019. Vaccination is considered the most effective measure to prevent the spread, hospitalizations, and deaths related to COVID-19. However, more studies focused on more specific populations such as people suffering from autoimmune rheumatic diseases are still needed to make better use of the available…
Acute COVID-19 infection typically takes about 2 weeks to resolve. Severe cases of acute infection can last for 3 or 6 weeks depending on the severity1,2. However, some patients have symptoms that can last for weeks or even months. The World Health Organization classifies as post-covid-19 syndrome, any persistent manifestation of at least 28 days after the first symptom of acute infection…
The COVID-19 pandemic has progressed rapidly worldwide, reaching lethality of up to 20% in different regions (Garcia LF, 2020). More severe cases were observed in elderly patients with comorbidities, particularly in those with chronic cardiovascular or respiratory diseases, diabetes and hypertension (Garcia LF, 2020; Emmi G, 2020). SARS-Cov-2 infection raised a particular concern in patie…
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing grants |
| 39 / 17 | Completed research grants |
| 33 / 14 | Completed scholarships in Brazil |
| 73 / 32 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID